Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status

Heng Hong, Chinghai Kao, Meei Huey Jeng, John N. Eble, Michael O. Koch, Thomas A. Gardner, Shaobo Zhang, Lang Li, Chong-Xian Pan, Zhiqiang Hu, Gregory T. MacLennan, Liang Cheng

Research output: Contribution to journalArticle

128 Citations (Scopus)

Abstract

BACKGROUND. Coactivator-associated arginine methyltransferase 1 (CARM1) is a transcriptional coactivator of the androgen receptor (AR). It is involved in the regulation of the biologic functions of the AR. It remains to be determined whether CARM1 is involved in prostatic carcinogenesis. METHODS. The expression of CARM1 in normal prostate epithelium, high-grade prostatic intraepithelial neoplasia (PIN), and prostate carcinoma tissue was examined in 66 previously untreated patients with prostate carcinomas, as well as 12 patients with hormone-independent prostate carcinoma, using immunohistochemical methods. RESULTS. Cell staining was observed in the cytoplasm and the nucleus. In 66 patients without previous hormonal treatment, the percentage of cells that stained positively for CARM1 in benign prostate tissue specimens (mean values: cytoplasm, 23%; nucleus, 16%) was statistically significantly less than the percentage of positively stained cells in PIN (mean values: cytoplasm, 56%; nucleus, 30%; P < 0.001) and in prostatic adenocarcinoma specimens (mean values: cytoplasm, 79%; nucleus, 53%; P < 0.001). The difference between adenocarcinoma and PIN also was statistically significant (P < 0.001). The staining intensity for CARM1 was significantly lower in benign prostate tissue specimens compared with PIN and prostatic adenocarcinoma specimens (P < 0.001). In the 12 patients with androgen-independent prostatic adenocarcinoma, the expression of CARM1 was significantly increased when compared with patients without previous hormonal treatment. Expression of CARM1 was not correlated with age, Gleason score sum, pathologic stage, lymph node metastasis, extraprostatic extension, surgical margin status, vascular invasion, or perineural invasion. CONCLUSIONS. The authors found that overexpression of CARM1 was involved in the development of prostate carcinoma as well as androgen-independent prostate carcinoma. Since CARM1 is functionally different from most other transcriptional coactivators of the AR, it may serve as a new target for the treatment of hormone-independent prostate carcinoma.

Original languageEnglish (US)
Pages (from-to)83-89
Number of pages7
JournalCancer
Volume101
Issue number1
DOIs
StatePublished - Jul 1 2004
Externally publishedYes

Fingerprint

Androgen Receptors
Androgens
Prostate
Carcinoma
Prostatic Intraepithelial Neoplasia
Cytoplasm
Adenocarcinoma
Hormones
Staining and Labeling
coactivator-associated arginine methyltransferase 1
Neoplasm Grading
Blood Vessels
Carcinogenesis
Therapeutics
Epithelium
Lymph Nodes
Neoplasm Metastasis

Keywords

  • Adenocarcinoma
  • Androgen-independent prostate cacinoma
  • Biomarkers
  • Carcinogenesis
  • Coactivator-associated arginine methyltransferase 1 (CARM1)
  • Prostate
  • Prostatic intraepithelial neoplasia

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status. / Hong, Heng; Kao, Chinghai; Jeng, Meei Huey; Eble, John N.; Koch, Michael O.; Gardner, Thomas A.; Zhang, Shaobo; Li, Lang; Pan, Chong-Xian; Hu, Zhiqiang; MacLennan, Gregory T.; Cheng, Liang.

In: Cancer, Vol. 101, No. 1, 01.07.2004, p. 83-89.

Research output: Contribution to journalArticle

Hong, H, Kao, C, Jeng, MH, Eble, JN, Koch, MO, Gardner, TA, Zhang, S, Li, L, Pan, C-X, Hu, Z, MacLennan, GT & Cheng, L 2004, 'Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status', Cancer, vol. 101, no. 1, pp. 83-89. https://doi.org/10.1002/cncr.20327
Hong, Heng ; Kao, Chinghai ; Jeng, Meei Huey ; Eble, John N. ; Koch, Michael O. ; Gardner, Thomas A. ; Zhang, Shaobo ; Li, Lang ; Pan, Chong-Xian ; Hu, Zhiqiang ; MacLennan, Gregory T. ; Cheng, Liang. / Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status. In: Cancer. 2004 ; Vol. 101, No. 1. pp. 83-89.
@article{aed2c754700a4a80af55211038406fa1,
title = "Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status",
abstract = "BACKGROUND. Coactivator-associated arginine methyltransferase 1 (CARM1) is a transcriptional coactivator of the androgen receptor (AR). It is involved in the regulation of the biologic functions of the AR. It remains to be determined whether CARM1 is involved in prostatic carcinogenesis. METHODS. The expression of CARM1 in normal prostate epithelium, high-grade prostatic intraepithelial neoplasia (PIN), and prostate carcinoma tissue was examined in 66 previously untreated patients with prostate carcinomas, as well as 12 patients with hormone-independent prostate carcinoma, using immunohistochemical methods. RESULTS. Cell staining was observed in the cytoplasm and the nucleus. In 66 patients without previous hormonal treatment, the percentage of cells that stained positively for CARM1 in benign prostate tissue specimens (mean values: cytoplasm, 23{\%}; nucleus, 16{\%}) was statistically significantly less than the percentage of positively stained cells in PIN (mean values: cytoplasm, 56{\%}; nucleus, 30{\%}; P < 0.001) and in prostatic adenocarcinoma specimens (mean values: cytoplasm, 79{\%}; nucleus, 53{\%}; P < 0.001). The difference between adenocarcinoma and PIN also was statistically significant (P < 0.001). The staining intensity for CARM1 was significantly lower in benign prostate tissue specimens compared with PIN and prostatic adenocarcinoma specimens (P < 0.001). In the 12 patients with androgen-independent prostatic adenocarcinoma, the expression of CARM1 was significantly increased when compared with patients without previous hormonal treatment. Expression of CARM1 was not correlated with age, Gleason score sum, pathologic stage, lymph node metastasis, extraprostatic extension, surgical margin status, vascular invasion, or perineural invasion. CONCLUSIONS. The authors found that overexpression of CARM1 was involved in the development of prostate carcinoma as well as androgen-independent prostate carcinoma. Since CARM1 is functionally different from most other transcriptional coactivators of the AR, it may serve as a new target for the treatment of hormone-independent prostate carcinoma.",
keywords = "Adenocarcinoma, Androgen-independent prostate cacinoma, Biomarkers, Carcinogenesis, Coactivator-associated arginine methyltransferase 1 (CARM1), Prostate, Prostatic intraepithelial neoplasia",
author = "Heng Hong and Chinghai Kao and Jeng, {Meei Huey} and Eble, {John N.} and Koch, {Michael O.} and Gardner, {Thomas A.} and Shaobo Zhang and Lang Li and Chong-Xian Pan and Zhiqiang Hu and MacLennan, {Gregory T.} and Liang Cheng",
year = "2004",
month = "7",
day = "1",
doi = "10.1002/cncr.20327",
language = "English (US)",
volume = "101",
pages = "83--89",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status

AU - Hong, Heng

AU - Kao, Chinghai

AU - Jeng, Meei Huey

AU - Eble, John N.

AU - Koch, Michael O.

AU - Gardner, Thomas A.

AU - Zhang, Shaobo

AU - Li, Lang

AU - Pan, Chong-Xian

AU - Hu, Zhiqiang

AU - MacLennan, Gregory T.

AU - Cheng, Liang

PY - 2004/7/1

Y1 - 2004/7/1

N2 - BACKGROUND. Coactivator-associated arginine methyltransferase 1 (CARM1) is a transcriptional coactivator of the androgen receptor (AR). It is involved in the regulation of the biologic functions of the AR. It remains to be determined whether CARM1 is involved in prostatic carcinogenesis. METHODS. The expression of CARM1 in normal prostate epithelium, high-grade prostatic intraepithelial neoplasia (PIN), and prostate carcinoma tissue was examined in 66 previously untreated patients with prostate carcinomas, as well as 12 patients with hormone-independent prostate carcinoma, using immunohistochemical methods. RESULTS. Cell staining was observed in the cytoplasm and the nucleus. In 66 patients without previous hormonal treatment, the percentage of cells that stained positively for CARM1 in benign prostate tissue specimens (mean values: cytoplasm, 23%; nucleus, 16%) was statistically significantly less than the percentage of positively stained cells in PIN (mean values: cytoplasm, 56%; nucleus, 30%; P < 0.001) and in prostatic adenocarcinoma specimens (mean values: cytoplasm, 79%; nucleus, 53%; P < 0.001). The difference between adenocarcinoma and PIN also was statistically significant (P < 0.001). The staining intensity for CARM1 was significantly lower in benign prostate tissue specimens compared with PIN and prostatic adenocarcinoma specimens (P < 0.001). In the 12 patients with androgen-independent prostatic adenocarcinoma, the expression of CARM1 was significantly increased when compared with patients without previous hormonal treatment. Expression of CARM1 was not correlated with age, Gleason score sum, pathologic stage, lymph node metastasis, extraprostatic extension, surgical margin status, vascular invasion, or perineural invasion. CONCLUSIONS. The authors found that overexpression of CARM1 was involved in the development of prostate carcinoma as well as androgen-independent prostate carcinoma. Since CARM1 is functionally different from most other transcriptional coactivators of the AR, it may serve as a new target for the treatment of hormone-independent prostate carcinoma.

AB - BACKGROUND. Coactivator-associated arginine methyltransferase 1 (CARM1) is a transcriptional coactivator of the androgen receptor (AR). It is involved in the regulation of the biologic functions of the AR. It remains to be determined whether CARM1 is involved in prostatic carcinogenesis. METHODS. The expression of CARM1 in normal prostate epithelium, high-grade prostatic intraepithelial neoplasia (PIN), and prostate carcinoma tissue was examined in 66 previously untreated patients with prostate carcinomas, as well as 12 patients with hormone-independent prostate carcinoma, using immunohistochemical methods. RESULTS. Cell staining was observed in the cytoplasm and the nucleus. In 66 patients without previous hormonal treatment, the percentage of cells that stained positively for CARM1 in benign prostate tissue specimens (mean values: cytoplasm, 23%; nucleus, 16%) was statistically significantly less than the percentage of positively stained cells in PIN (mean values: cytoplasm, 56%; nucleus, 30%; P < 0.001) and in prostatic adenocarcinoma specimens (mean values: cytoplasm, 79%; nucleus, 53%; P < 0.001). The difference between adenocarcinoma and PIN also was statistically significant (P < 0.001). The staining intensity for CARM1 was significantly lower in benign prostate tissue specimens compared with PIN and prostatic adenocarcinoma specimens (P < 0.001). In the 12 patients with androgen-independent prostatic adenocarcinoma, the expression of CARM1 was significantly increased when compared with patients without previous hormonal treatment. Expression of CARM1 was not correlated with age, Gleason score sum, pathologic stage, lymph node metastasis, extraprostatic extension, surgical margin status, vascular invasion, or perineural invasion. CONCLUSIONS. The authors found that overexpression of CARM1 was involved in the development of prostate carcinoma as well as androgen-independent prostate carcinoma. Since CARM1 is functionally different from most other transcriptional coactivators of the AR, it may serve as a new target for the treatment of hormone-independent prostate carcinoma.

KW - Adenocarcinoma

KW - Androgen-independent prostate cacinoma

KW - Biomarkers

KW - Carcinogenesis

KW - Coactivator-associated arginine methyltransferase 1 (CARM1)

KW - Prostate

KW - Prostatic intraepithelial neoplasia

UR - http://www.scopus.com/inward/record.url?scp=3042536209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042536209&partnerID=8YFLogxK

U2 - 10.1002/cncr.20327

DO - 10.1002/cncr.20327

M3 - Article

C2 - 15221992

AN - SCOPUS:3042536209

VL - 101

SP - 83

EP - 89

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -